PEP07

DRUG2 trials

Sponsors

PharmaEngine

Conditions

Acute Myeloid LeukemiaAdvanced Solid TumorLymphoma, Mantle-CellMetastatic Solid Tumor

Phase 1

A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer

RecruitingNCT05659732

PharmaEngineAcute Myeloid Leukemia, Lymphoma, Mantle-Cell

Start: 2023-07-17End: 2026-12-31Target: 32Updated: 2025-07-31

A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients with Advanced or Metastatic Solid Tumors

RecruitingNCT05983523

PharmaEngineAdvanced Solid Tumor, Metastatic Solid Tumor

Start: 2024-03-27End: 2027-08-31Target: 54Updated: 2024-11-07

Related Papers

Abstract 1762: Preclinical and clinical studies of PEP07, a novel brain penetrating oral Chk1 inhibitor, on AML and MCL treatments

Cancer Research2025-04-21

Abstract 5638: Preclinical and clinical studies of PEP07, a novel brain penetrating Chk1 inhibitor, on solid tumor treatments

Cancer Research2025-04-21